Merck and Eisai have secured approval from the US Food and Drug Administration (FDA) for Keytruda (pembrolizumab) plus Lenvima (lenvatinib) combination to treat patients with certain types of advanced endometrial carcinoma.
23 Jul 2021
22 Jul 2021
AstraZeneca has completed the acquisition of biopharmaceutical company Alexion Pharmaceuticals in a deal valued at $39bn.
21 Jul 2021
Roche has received Japan’s Ministry of Health, Labour and Welfare (MHLW) approval for its Ronapreve to treat mild to moderate Covid-19 patients.
08 Jul 2021
The US Food and Drug Administration (FDA) has accepted the biologics licence application (BLA) and granted priority review for tezepelumab, which is being developed by AstraZeneca and Amgen, to treat patients with asthma.
07 Jul 2021
The European Commission has cleared AstraZeneca’s proposed acquisition of Alexion Pharmaceuticals for $39bn.
02 Jul 2021
Seres Therapeutics and Nestlé Health Science have signed an agreement to jointly commercialise SER-109, an investigational oral microbiome therapy, in the US and Canada.
28 Jun 2021
Johnson & Johnson (J&J) has reached a $230m agreement to settle the opioid-related claims with the New York State and its participating subdivisions Nassau County and Suffolk County.
25 Jun 2021
The US Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for Roche’s Actemra (tocilizumab) to treat hospitalised Covid-19 patients.
24 Jun 2021
Eisai and Biogen have received breakthrough therapy designation from the US Food and Drug Administration (FDA) for their Alzheimer’s disease drug candidate, lecanemab (BAN2401).
17 Jun 2021
Novartis has secured breakthrough therapy designation from the US Food and Drug Administration (FDA) for 177Lu-PSMA-617 to treat metastatic castration-resistant prostate cancer (mCRPC).